pharma · Multiple Myeloma · Recurrent glioblastoma
Oncopeptides AB (publ)
Oncopeptides AB (publ) is a pharma organization headquartered in EU. Primary therapeutic focus areas include Multiple Myeloma, Recurrent glioblastoma. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0
Stockholm, SE HQ
2000 Founded
85 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Stockholm, SE
- Founded
- 2000
- Employees
- 85
- Programs
- 2
- Drugs
- 2
- Patents
- 0
Melflufen
Phase 3 · small molecule · Multiple Myeloma
Melflufen for Multiple Myeloma is a Phase 3 program (small_molecule) at Oncopeptides AB (publ) with 1 ClinicalTrials.gov record(s).
Internal code OP-103
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Oncopeptides AB (publ)
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Multiple Myeloma
- Status
- terminated
- Trials
- 1